Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.12 USD | +1.54% | +13.96% | -14.04% |
05-09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
05-09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.04% | 2.48B | |
+26.23% | 49.18B | |
+0.57% | 42.11B | |
+50.24% | 40.37B | |
-5.26% | 28.85B | |
+12.34% | 26.09B | |
-21.90% | 18.71B | |
+8.51% | 13.26B | |
+31.14% | 12.32B | |
-0.21% | 11.99B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- RBC Cuts Intellia Therapeutics' Price Target to $90 From $100, Keeps Outperform Speculative Risk Rating